US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults

50

LONDON–(BUSINESS WIRE)–ViiV Healthcare announces FDA approval of Dovato for treatment-naive adults with HIV-1 http://www.businesswire.com/news/home/20190408005806/en/FDA-approves-ViiV-Healthcare%E2%80%99s-Dovato-dolutegravirlamivudine-once-daily/?feedref=JjAwJuNHiystnCoBq_hl-WFAllVCLJFCqzlmaJ8DKHU4plfPZtlGYRDUHCSmgbii6XkLWuQZD-HgGRnjQvCyg3iCfEFIaJW7-otp9V1XQiK2eHTJy3ZqOEt7kKgLu20J